At the time of writing of this article, the world was battling the unprecedented coronavirus pandemic disease, the so-called COVID-19.
A well-known antimalarial drug chloroquine, its derivative hydroxychloroquine and other antivirals which are known to inhibit viral entry into host cells by increasing endosomal pH have been introduced in an attempt to treat COVID-19 [10].
There are currently 197 clinical trials assessing the role of antimalarials alone or in combination with other agents against COVID-19 infection [12], [13].
These poor results highlight the need to test for G6PD deficiency prior to enrolment in clinical trials evaluating antimalarials and other oxidizing drugs in COVID-19.